| Title |
Profile of dupilumab and its potential in the treatment of inadequately controlled moderate-to-severe atopic dermatitis
|
|---|---|
| Published in |
Clinical, Cosmetic and Investigational Dermatology, January 2018
|
| DOI | 10.2147/ccid.s123329 |
| Pubmed ID | |
| Authors |
Olabola Awosika, Lori Kim, Momina Mazhar, Monica Rengifo-Pardo, Alison Ehrlich |
| Abstract |
Atopic dermatitis (AD) is a common inflammatory skin disorder that manifests as eczematous lesions, often associated with allergic rhinitis and asthma. Historically, moderate-to-severe disease has been managed with systemic immunosuppression, such as oral corticosteroids, which result in relapse and limiting side effects. Due to recent advancements in the identification of interleukin (IL)-4 and IL-13 as key mediators in AD, new biological agents have been developed for treatment. Dupilumab is a recently approved monoclonal antibody that targets the alpha subunit of the IL-4 receptor and, thus, downregulates activity of IL-4 and IL-13. This review discusses the profile of dupilumab and its potential for efficacy and safety in treating moderate-to-severe AD by reviewing data from Phase I-III clinical trials. Results suggest that dupilumab shows great therapeutic promise for AD. Further studies investigating extended use of dupilumab and dupilumab in comparison to other agents are needed to establish long-term efficacy and safety. |
Mendeley readers
The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 58 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 7 | 12% |
| Researcher | 7 | 12% |
| Student > Bachelor | 7 | 12% |
| Student > Ph. D. Student | 5 | 9% |
| Student > Postgraduate | 5 | 9% |
| Other | 13 | 22% |
| Unknown | 14 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 29% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 12% |
| Biochemistry, Genetics and Molecular Biology | 7 | 12% |
| Immunology and Microbiology | 2 | 3% |
| Nursing and Health Professions | 1 | 2% |
| Other | 4 | 7% |
| Unknown | 20 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 January 2018.
All research outputs
#17,292,294
of 25,382,440 outputs
Outputs from Clinical, Cosmetic and Investigational Dermatology
#558
of 905 outputs
Outputs of similar age
#283,799
of 449,550 outputs
Outputs of similar age from Clinical, Cosmetic and Investigational Dermatology
#10
of 13 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 905 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.2. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 449,550 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.